Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats

Diabetologia

Volumn 40, Issue 10, 1997, Pages 1141-1151

  Soulis, T ^a   Cooper, M E ^a   Sastra, S ^a   Thallas, V ^a   Panagiotopoulos, S ^a   Bjerrum, O J ^b   Jerums, G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Advanced glycation end products; Aminoguanidine; Diabetic nephropathy; L NAME; Methylguanidine; Nitric oxide

Indexed keywords

AMINOGUANIDINE; HEMOGLOBIN A1C; METHYLGUANIDINE; N(G) NITROARGININE METHYL ESTER; NITRATE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INDUCTION; GLOMERULUS FILTRATION RATE; GLYCATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

ADMINISTRATION, ORAL; ALBUMINURIA; ANIMALS; COHORT STUDIES; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MALE; METHYLGUANIDINE; NG-NITROARGININE METHYL ESTER; NITRATES; NITRIC OXIDE SYNTHASE; NITRITES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0030863382     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050799     Document Type: Article

References (60)

1. Monnier V, Vishwanath V, Frank K, Elmets G, Dauchot P, Kohn R (1986) Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Eng J Med 314: 403-408
2. Nicholls K, Mandel T (1989) Advanced glycosylation end products in experimental murine diabetic nephropathy: effect of islet grafting and of aminoguanidine. Lab Invest 60: 486-489
3. Hammes H, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558
4. Cameron NE, Cotter MA, Dines K, Love A (1992) Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35: 946-950
5. Soulis-Liparota T, Cooper ME, Papazoglou D, Clarke B, Jerums G (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334
6. Bucala R, Vlassara H (1995) Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26: 875-888
7. Makita Z, Vlassara H, Rayfield E, et al. (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258: 651-653
8. Tilton RG, Chang K, Hasan KS, et al. (1993) Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42: 221-232
9. Komers R, Allen TJ, Cooper ME (1994) Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 43: 1190-1197
10. Bank S, Aynedjian H (1993) Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43: 1306-1312
11. Nguyen D, Panagiotopoulos S, Soulis T, Cooper M, Jerums G (1995) Aminoguanidine and methylguanidine reduce mesenteric vascular enlargement in experimental diabetes. Diabetologia 38 [Suppl 1]: A255 (Abstract)
12. Rumble J, Komers R, Cooper M (1995) Kinins or nitric oxide, or both, are involved in the antitropic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens 14: 601-607
13. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G (1996) The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 50: 627-634
14. Schmidt F (1961) Enzymatic determination of glucose and fructose simultaneously. Klin Woch 39: 1244-1247
15. Bunag R (1973) Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34: 279-282
16. Allen TJ, Cooper ME, O'Brien RC, Bach LA, Jackson B, Jerums G (1990) Glomerular filtration rate in streptozocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 39: 1182-1190
17. Bartholomew B (1984) A rapid method for the assay of nitrate reductase enzyme of Escherichia coli. Food Chem Toxicol 22: 541-543
18. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632
19. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
20. Salacinski P, McLean C, Sykes J, Clement-Jones W, Lowry P (1981) Iodination of proteins, glycoproteins and peptides using a solid phase oxidising agent, 1,3,4,6-1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Anal Biochem 117: 136-146
21. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW (1995) N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878
22. Bjerrum OJ, Ingild A, Lowenstein H, Weeke B (1973) Quantitation of human IgG by rocket immunoelectrophoresis at pH5 by use of carbamylated antibodies: a routine laboratory method. Clin Chim Acta 46: 337-343
23. Rumble JR, Cooper ME, Soulis T, et al. (1997) Vascular remodeling in experimental diabetes: role of advanced glycation end products. J Clin Invest 99: 1016-1027
24. Makita Z, Vlassara H, Cerami A, Bucala R (1992) Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267: 5133-5138
25. Sell DR, Monnier VM (1990) End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85: 380-384
26. Vlassara H, Bucala R, Striker L (1990) Pathogenic effects of advanced glycosylation: biochemical, biological and clinical implications for diabetes and aging. J Lab Invest 70: 138-151
27. McCance DR, Dyer DG, Dunn JA, et al. (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478
28. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G (1995) The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38: 387-394
29. Corbett JA, Tilton RG, Chang K, et al. (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556
30. Worrall N, Misko T, Sullivan P, Hui J, Rodi C, Ferguson T (1996) Corticosteroids inhibit expression of inducible nitric oxide synthase during acute cardiac allograft rejection. Transplantation 61: 324-328
31. Mourelle M, Vilaseca J, Guarner F, Salas A, Malagelaida J (1996) Toxic dilation of colon in a rat model of colitis is linked to inducible form of nitric oxide synthase. Am J Physiol 33: G425-G430
32. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM (1993) Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Physiol 265: F886-F889
33. Wu G (1995) Nitric oxide synthesis and the effect of aminoguanidine and NG-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 44: 360-364
34. Reyes A, Karl I, Kissane J, Klahr S (1993) L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Neph 43: 1039-1045
35. Ahn K, Mohaupt M, Madsen K, Kone B (1996) In situ hybridisation localisation of mRNA encoding iNOS in rat kidney. Am J Physiol 34: F748-F757
36. Morrisey J, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S (1994) Location of inducible nitric oxide synthase mRNA in the normal kidney. Kidney Internat 45: 998-1005
37. Ruetten H, Thiemermann C (1996) Prevention of the expression of inducible nitric oxide synthase by aminoguanidine or amino-ethyl-isothiourea in macrophages and in the rat. Biochem Biophys Res Comm 225: 525-530
38. King A, Zayas M, Troy J, Downes S, Brenner B (1990) Inhibition of diabetes-induced hyperfiltration and hyperemia by N-omega-monomethyl-L-arginine (L-NMMA). J Am Soc Nephrol 1: 666 (Abstract)
39. Mattar A, Fujihara C, Ribeiro M, Denucci G, Zatz R (1996) Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron 74: 136-143
40. Tesfamariam B, Brown M, Cohen R (1991) Elevated glucose impairs endothelium-dependent relaxation. J Clin Invest 87: 1643-1648
41. Meraji S, Jayakody L, Senarantine M, Thomson A, Kappagoda T (1987) Endothelium-dependent relaxation in aorta of BB rat. Diabetes 36: 978-981
42. Dyer DG, Dunn JA, Thorpe SR, et al. (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469
43. Nyengard J, Chang K, Berhorst S, Reiser K, Williamson J, Tilton R (1997) Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes 46: 94-106
44. Fu MX, Wells Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW (1994) Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43: 676-683
45. Van der Vliet A, Smith D, O'Neill CA, et al. (1994) Interactions of peroxynitrite with human plasma and its constituents: oxidative damage and antioxidant depletion. Biochem J 303: 295-301
46. Haddad IY, Crow JP, Hu P, Ye Y, Beckman J, Matalon S (1994) Concurrent generation of nitric oxide and superoxide damages surfactant protein. Am J Physiol 267: L242-L249
47. Rubbo H, Radi R, Trujillo M, et al. (1994) Nitric oxide regulation of superoxide and peroxynitrite dependent lipid peroxidation. Formation of novel nitrogen-containing oxidised lipid derivatives. J Biol Chem 269: 26066-26075
48. Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412
49. Kochakian M, Manjula B, Egan J (1996) Chronic dosing with aminoguanidine and novel advanced glycosylation end product formation inhibitors ameliorates cross-linking of tail tendon collagen in streptozotocin-induced diabetic rats. Diabetes 45: 1694-1700
50. Hasan K, Heesen B, Corbett J, et al. (1993) Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 249: 101-106
51. Corbett JA, McDaniel ML (1992) Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic interventions in IDDM. Diabetes 41: 897-903
52. Bucala R, Tracey K, Cerami A (1991) Advanced glycosylation products quench nitric oxide and mediated defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87: 432-438
53. Hogan M, Cerami A, Bucala R (1992) Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 90: 1110-1115
54. Williamson JR, Chang K, Frangos M, et al. (1993) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813
55. Farkas J, Menzel E (1995) Proteins lose their nitric oxide stabilising function after advanced glycosylation. Biochim Biophys Acta 1245: 305-310
56. Cooper ME, Allen TJ, Macmillan P, et al. (1988) Effects of genetic hypertension on diabetic nephropathy in the rat: functional and structural characteristics. J Hypertens 6: 1009-1016
57. Zatz R, Dunn B, Meyer T, Anderson S, Rennke H, Brenner B (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930
58. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ (1994) Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91: 9436-9440
59. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker G, Striker L (1992) Receptor specific increases in extracellular matrix productions in mouse mesangial cells by AGEP is mediated via platelet growth factor. Proc Natl Acad Sci USA 89: 2843-2877
60. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R (1992) Exogenous advanced glycation end products induce complex vascular dysfunction in normal animals. Proc Natl Acad Sci USA 89: 12043-12047